Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6469 Neoadjuvant in Head and Neck Cancer
NCT02274155Phase 1Completed
- Start
- Nov 2014
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of medi-6469 in head and neck squamous cell carcinoma (HNSCC) (3 arms). Primary endpoint: Safety and feasibility of definitive surgical resection at 55 days. Started Nov 2014; status: completed.
02
Drugs
medi-6469
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02274155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274155.